Role of a New Walk Test in Pulmonary Arterial Hypertension: A Retrospective Cohort Study

Figures

• 

  Figure 1. Study flowchart. CTEPH, chronic thromboembolic pulmonary hypertension; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 6MWT, 6‐min walk test; 18MWT, 18‐meter walk test; PAH, pulmonary arterial hypertension; PH‐FM, pulmonary hypertension caused by fibrosing mediastinitis; prec‐PH, pre‐capillary pulmonary hypertension.

• 

  Figure 2. Correlation and consistency between the 18MWT and 6MWT in patients with PAH. (A) Scatter plot indicating the correlation between 18MWT time and 6MWT distance; (B) Bland‐Altman plot showing the agreement between 18MWT and 6MWT. 6MWT, 6‐min walk test; 18MWT, 18‐meter walk test; PAH, pulmonary arterial hypertension.

• 

  Figure 3. Kaplan–Meier curve for patients with PAH classified by baseline results of 18MWT.

• 

  Figure 4. Validation of risk stratification for prediction of clinical worsening in PAH. (A) ROC curves comparing the predictive performance of REVEAL Lite 2, the FPHR invasive method, and the simplified risk score for 1‐year clinical worsening. (B) ROC curves for the FPHR non‐invasive method and its modified versions: one replacing the 6MWT distance with the 18MWT time, and another incorporating the 18MWT time as an additional variable. FPHR, French pulmonary hypertension registry; 6MWT, 6‐min walk test; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; PAH, pulmonary arterial hypertension; REVEAL, Registry to Evaluate Early and Long‐Term PAH Disease Management; ROC, receiver operator characteristic; WHO‐FC, World Health Organization functional class.

• 

  Figure 5. Forest plot of HRs of 18MWT completion time by patient subgroups. HR, hazard ratio; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; 6MWT, 6‐min walk test; 18MWT, 18‐meter walk test; PVR, pulmonary vascular resistance; WHO‐FC, World Health Organization functional class.